Printer-friendly versionPrinter-friendly version

2018 - Reference list of hepatitis publications of the VHPB board members

Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries.
Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, Veldhuijzen IK.
BMC Infect Dis. 2018 Jan 11;18(1):34. doi: 10.1186/s12879-017-2921-8. No abstract available.
Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP.
Clin Infect Dis. 2018 Feb 6. doi: 10.1093/cid/ciy098.
Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK.
BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x.
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M.
J Hepatol. 2018 Mar;68(3):402-411. doi: 10.1016/j.jhep.2017.10.010.
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID).
Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.
Miglietta A, Quinten C, Lopalco PL, Duffell E.
Euro Surveill. 2018 Feb;23(6). doi: 10.2807/1560-7917.ES.2018.23.6.17-00278.
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
Valerio H, McAuley A, Innes H, Palmateer N, Goldberg DJ, Munro A, Taylor A, Hutchinson SJ.
Int J Drug Policy. 2018 Feb;52:115-122. doi: 10.1016/j.drugpo.2017.12.014.

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M.

J Hepatol. 2018 Mar;68(3):402-411. doi: 10.1016/j.jhep.2017.10.010. Epub 2018 Jan 8.


Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. 

Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, Veldhuijzen IK.

BMC Infect Dis. 2018 Jan 11;18(1):34.  


Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK.

BMC Infect Dis. 2018 Jan 16;18(1):42.  


The HepHIV 2017 Conference in Malta: joining forces for the earlier diagnosis of HIV and viral hepatitis.

Raben D, Hoekstra M, Sperle I, Amato Gauci AJ, Gauci C, West B, Sullivan A, Lazarus JV, Platteau T, Rockstroh JK; HepHIV Conference Organising Committee and the HIV in Europe Steering Committee.

HIV Med. 2018 Feb;19 Suppl 1:5-10. doi: 10.1111/hiv.12588.


The benefits of hepatitis C virus cure: Every rose has thorns.

Salmon D, Mondelli MU, Maticic M, Arends JE; ESCMID Study Group for Viral Hepatitis.

J Viral Hepat. 2018 Apr;25(4):320-328. doi: 10.1111/jvh.12823. Epub 2018 Feb 19.


Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016).

Aspinall EJ, Hutchinson SJ, Goldberg DJ, Valerio H, Mozalevskis A, Noori T, Duffell E, Tavoschi L.

HIV Med. 2018 Feb;19 Suppl 1:11-15. 


Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.

Miglietta A, Quinten C, Lopalco PL, Duffell E.

Euro Surveill. 2018 Feb;23(6).


Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.

Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK.

BMC Infect Dis. 2018 Feb 12;18(1):79.  


Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.

Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group.

Aliment Pharmacol Ther. 2018 Apr;47(8):1170-1180. doi: 10.1111/apt.14560. Epub 2018 Mar 2.


High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ.

J Hepatol. 2018 Aug;69(2):293-300. doi: 10.1016/j.jhep.2018.03.007. Epub 2018 Mar 16.


Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyPolaris Observatory Collaborators.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27.


Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination programme.

Godoy P, Carmona G, Manzanares S, Jané M, Borràs E, Camps N, Álvarez J, Barrabeig I, Sala MR, Rius C, Minguell S, Carol M, Ferras J, Domínguez A, Working Group for the Study of Hepatitis in Catalonia.

J Viral Hepat. 2018 Sep;25(9):1001-1007. doi: 10.1111/jvh.12900. Epub 2018 Apr 26.


Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.


Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network.

Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26.


The Dark Side of the Long-Term Use of Proton Pump Inhibitors in Chronic Liver Disease.

Fernandes SR, Tato Marinho R.

GE Port J Gastroenterol. 2019 Mar;26(2):79-80. doi: 10.1159/000489640. Epub 2018 May 25.


Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.

Lazarus JV, Stumo SR, Harris M, Hendrickx G, Hetherington KL, Maticic M, Jauffret-Roustide M, Tallada J, Simojoki K, Reic T, Safreed-Harmon K; Hep-CORE Study Group.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25052. doi: 10.1002/jia2.25052.


High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles.

Prakash K, Rydell GE, Larsson SB, Andersson M, Norkrans G, Norder H, Lindh M.

Virol J. 2018 May 15;15(1):86. doi: 10.1186/s12985-018-0994-7. PubMed PMID: 29764511; PubMed Central PMCID: PMC5952638.


Viral envelope-specific antibodies in chronic hepatitis B virus infection.

Corti D, Benigni F, Shouval D.

Curr Opin Virol. 2018 Jun;30:48-57. Review


Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.

Velati C, Romanò L, Piccinini V, Marano G, Catalano L, Pupella S, Facco G, Pati I, Tosti ME, Vaglio S, Grazzini G, Zanetti A, Liumbruno GM.

Blood Transfus. 2018 Sep;16(5):422-432. doi: 10.2450/2018.0069-18. Epub 2018 Jun 26.


Assessing the cost-effectiveness of hepatitis C screening strategies in France.

Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y.

J Hepatol. 2018 Oct;69(4):785-792. doi: 10.1016/j.jhep.2018.05.027. Epub 2018 Jul 1.


Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.


Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19


Hepatitis C virus infection: 'beyond the liver'.

Arrais de Castro R, Vilas P, Borges-Costa J, Tato Marinho R.

BMJ Case Rep. 2018 Jul 25;2018. pii: bcr-2018-225817. doi: 10.1136/bcr-2018-225817.


Continuous decline of hepatitis E virus seroprevalence in southern Germany despite increasing notifications, 2003–2015.

Mahrt H, Schemmerer M, Behrens G, Leitzmann M, Jilg W, Wenzel JJ.

Emerg Microbes Infect. 2018 Jul 25;7(1):133. doi: 10.1038/s41426-018-0136-8.


Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.

Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups.

Liver Int. 2019 Jan;39(1):136-146. doi: 10.1111/liv.13921. Epub 2018 Jul 30.


Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.

Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N.

Sci Rep. 2018 Aug 16;8(1):12266. doi: 10.1038/s41598-018-30528-0.


TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands.

Buschow SI, Biesta PJ, Groothuismink ZMA, Erler NS, Vanwolleghem T, Ho E, Najera I, Ait-Goughoulte M, de Knegt RJ, Boonstra A, Woltman AM.

Antiviral Res. 2018 Sep;157:27-37. doi: 10.1016/j.antiviral.2018.06.015. Epub 2018 Jun 28.


Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis.

Bastard JP, Fellahi S, Audureau É, Layese R, Roudot-Thoraval F, Cagnot C, Mahuas-Bourcier V, Sutton A, Ziol M, Capeau J, Nahon P; ANRS CO12 CirVir group.

Eur Cytokine Netw. 2018 Sep 1;29(3):112-120. doi: 10.1684/ecn.2018.0413.


Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M,14, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Liver Int. 2019 Jan;39(1):20-30. doi: 10.1111/liv.13949. Epub 2018 Sep 22.


Distribution of hepatitis B virus genotypes in Europe and clinical implications: a review.

Kmet Lunaček N, Poljak M, Matičič M.

Acta Dermatovenerol Alp Pannonica Adriat. 2018 Sep;27(3):141-146.


Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.

Trabut JB, Barrault C, Charlot H, Carmona D, Bourdel A, Benslimane M, François M, Kini-Matondo W, Causse R, Roudot-Thoraval F, Hézode C.

J Addict Med. 2018 Sep/Oct;12(5):346-352. doi: 10.1097/ADM.0000000000000415.


Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.

Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M. 

J Virol. 2018 Sep 12;92(19). pii: e01087-18. doi: 10.1128/JVI.01087-18. Print 2018 Oct 1. PubMed PMID: 30045981; PubMed Central PMCID: PMC6146798.


Hepatitis E Virus Genotype 3 Genomes from RNA-Positive but Serologically Negative Plasma Donors Have CUG as the Start Codon for ORF3.

Norder H, Galli C, Magnil E, Sikora P, Ekvärn E, Nyström K, Magnius LO.

Intervirology. 2018;61(2):96-103. doi: 10.1159/000491926. Epub 2018 Oct 2. PubMed PMID: 30278453; PubMed Central PMCID: PMC6262685.


Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1534-1548. doi: 10.1002/hep.29927.


Hepatitis E in Italy: 5 years of national epidemiological, virological and environmental surveillance, 2012 to 2016.

Alfonsi V, Romanò L, Ciccaglione AR, La Rosa G, Bruni R, Zanetti A, Della Libera S, Iaconelli M, Bagnarelli P, Capobianchi MR, Garbuglia AR, Riccardo F, Tosti ME; Collaborating Group.

Euro Surveill. 2018 Oct;23(41). doi: 10.2807/1560-7917.ES.2018.23.41.1700517.


ICTV Virus Taxonomy Profile: Deltavirus.

Magnius L, Taylor J, Mason WS, Sureau C, Dény P, Norder H, Ictv Report Consortium.  

J Gen Virol. 2018 Dec;99(12):1565-1566. doi: 10.1099/jgv.0.001150. Epub 2018 Oct 12. PubMed PMID: 30311870.


Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues.

Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance.

J Viral Hepat. 2019 Feb;26(2):278-286. doi: 10.1111/jvh.13025. Epub 2018 Nov 14.


Reply.

Costentin CE, Layese R, Roudot-Thoraval F, Audureau E, Nahon P; ANRS C012 CirVir group.

Gastroenterology. 2019 Jan;156(1):289-290. doi: 10.1053/j.gastro.2018.11.046. Epub 2018 Nov 23.

Hepatitis A surveillance: sensitivity of two information sources.  

Carmona G, Vilaró M, Ciruela P, Jané M, Giralt L, Ruiz L, Hernández S, Domínguez A, Working Group of the Epidemiological Surveillance Network of Catalonia and Working Group of the Microbiological Reporting System of Catalonia.

BMC Infect Dis. 2018; 18: 633. Published online 2018 Dec 7. doi: 10.1186/s12879-018-3552-4


Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.


Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?

Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F.

PLoS One. 2018 Dec 31;13(12):e0209374. doi: 10.1371/journal.pone.0209374. eCollection 2018.


Hepatitis C Prevention and Control Programme in Catalonia (2018).

Bruguera M, Dominguez A.

http://salutpublica.gencat.cat/web/.content/minisite/aspcat/vigilancia_salut_publica/vih-sida-its/04_Hepatitis_viriques/Plan-Hepatitis-Definitivo_C_DEF_ES.pdf; http://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/vih-sida-its-hv/Hepatitis-viriques/Plans-dactuacio/descripcio/